JATT II Acquisition Corp announced that it has priced an initial public offering of 6 million ordinary shares at $10.00 per share, producing gross proceeds of $60 million. The special purpose acquisition company intends for its ordinary shares to commence trading on the NASDAQ stock market under the ticker symbol JATT on April 17, 2026.
The offering is scheduled to formally close on April 20, 2026, and remains subject to customary closing conditions. Guggenheim Securities is acting as sole book-running manager for the transaction.
The company has provided the underwriters with a 45-day option to purchase up to an additional 900,000 ordinary shares at the IPO price to cover any over-allotments. The Securities and Exchange Commission declared the registration statement effective on April 16, 2026.
JATT II Acquisition Corp is a newly incorporated blank check company organized as a Cayman Islands exempted company. The entity was formed with the objective of effecting mergers, capital stock exchanges, asset acquisitions, reorganizations or similar business combinations with one or more businesses or entities.
According to the company's statement, it intends to concentrate its search on healthcare and healthcare-related businesses, placing particular emphasis on the biotechnology and life sciences sectors. The company said it will target businesses that apply data-driven approaches - including machine learning and computational biology - with the aim of improving therapeutic discovery and development processes.
JATT Ventures II L.P. is the sponsor of the blank check company. Dr. Someit Sidhu serves as Chief Executive Officer and Chairman of the Board, and Nicholas Fernandez is the company's Chief Financial Officer. The board of directors includes Verender S. Badial, Arjun Goyal, Jonathon Kluft and Christopher Staral.
The company has not selected any specific business combination target and has not engaged in substantive discussions with potential targets, the company said in its release.
Context and operational details
The structure of the offering - a 6 million share issuance at a standard $10 per share SPAC price, coupled with a 45-day over-allotment option for up to 900,000 additional shares - follows common market mechanics for special purpose acquisition companies. The SEC's effectiveness determination on April 16, 2026, clears a key regulatory step for the deal to proceed to its anticipated trading start date.
Governance and sponsorship
The sponsor and management team are identified, with governance overseen by a five-member board. The company is positioned to seek targets in sectors where computational methods are increasingly applied to drug discovery and development; however, at present no targets have been selected and there have been no substantive discussions with prospective targets.
Investors and market participants will watch for subsequent filings and disclosures as the company moves from a capital formation milestone toward the next phase of deal sourcing and potential negotiations.